SCHEMBL12830969

SCHEMBL12830969

COc1c(F)ccc(-c2scc(NC(=O)c3cc4ccccc4o3)c2C(=O)O)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.50
▸ RAB9A P51151 7/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ KMT2A Q03164 5/20 0.49
▸ CACNA1B Q00975 4/20 0.49
▸ APBA1 Q02410 4/20 0.49
▸ KDM4E B2RXH2 5/20 0.48
▸ HPGD P15428 4/20 0.48
▸ HSD17B10 Q99714 4/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ TSHR P16473 4/20 0.47
▸ TP53 P04637 4/20 0.47
▸ TAAR1 Q96RJ0 1/20 0.46
▸ MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12756430 0.89 RAB9A (0.55) NPC1RAB9ASMN1; SMN2L3MBTL1KMT2A
SCHEMBL12756444 0.88 NPC1 (0.47) NPC1RAB9ASMN1; SMN2L3MBTL1KMT2A
SCHEMBL12830118 0.86 RAB9A (0.53) NPC1RAB9ASMN1; SMN2L3MBTL1KMT2A
SCHEMBL12756433 0.86 RAB9A (0.50) NPC1RAB9ASMN1; SMN2L3MBTL1KMT2A
SCHEMBL12756445 0.86 RAB9A (0.55) NPC1RAB9ASMN1; SMN2L3MBTL1KMT2A
SCHEMBL1908085 0.85 KMT2A (0.48) NPC1RAB9ASMN1; SMN2L3MBTL1KMT2A
SCHEMBL12756441 0.85 KDM4E (0.52) NPC1RAB9ASMN1; SMN2L3MBTL1KDM4E
SCHEMBL12756432 0.84 KDM4E (0.48) NPC1RAB9ASMN1; SMN2L3MBTL1KMT2A
SCHEMBL12830020 0.84 RAB9A (0.50) NPC1RAB9ASMN1; SMN2L3MBTL1KMT2A
SCHEMBL12756434 0.84 KDM4E (0.53) NPC1RAB9ASMN1; SMN2L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 — — US disclosed
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 — — US disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885RAB9A 1174/4885SMN1; SMN2 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback